1Steinherz LJ,Steinherz PG,Tan CT, et al. Cardiac toxicity 4 to 20years after completing anthracycline therapy[J]. JAMA, 1991,266(12): 1672 - 1677.
2Shan KA, Lincoff M, Young JB. Anthracycline - induced cardiocytoxicity[J]. Annals of Internal Medicin, 1996,125 (1): 47 - 58.
3Kremer LCM, Vander Pal HJH, Offringa M, et al. Frequency and risk factors of subcliical cardiotoxicity after anthracycline therapy in children: A systematic review[J]. Annals Oncol, 2002, 13:819 -829.
4Bu'Lock FA, Martin RP, Mott MG. Increased risk of cardiac dysfunction after anthracyclines in girls[J]. Med Pediatr Oncol, 1995,24(2): 143 - 144.
5Horenstein MS, Vander Heide RS, L'ecuyer TJ. Molecular basis of anthracycline- induced cardiotoxicity and its prevention [J]. Mol Genet Metab, 2000,71 ( 1 - 2): 436 - 444.
6Giorgio M, Gaetano C, Elena M. Role of iron in anthracycline cardiotoxicity: new tunes for an old song[J]? FASEB J, 1999, 13(2): 199 - 212.
7Swift L, McHowat J, Sarvazyan N. Inhibition of membrane - associated calcium - independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity[J]. Cancer Res, 2003,63(18) :5992- 5998.
8Zhu WD, Zou YZ, Aikawa R, et al. MAPK superfamily plays an important role in daunomycin - induced apoptosis of cardiac myocytes[J]. Circulation,1999,100(20):2100-2107.
9Kim Y, Ma AG, Kitta K, et al. Anthracycline- induced suppression of GATA- 4 transcription factor: implication in the regulation of cardiac myocyte apoptosis[J]. Mol Pharmacol, 2003,63 (2): 368 -377.
10Safra T. Cardiac safety of liposomal anthracyclines[J]. Oncologist,2003,8 (suppl 2): S17 - S24.
